DC Field | Value |
---|---|
dc.contributor.author | Sylvia Park |
dc.contributor.author | Eun-Ja Park |
dc.date.accessioned | 2012-07-19T01:41:45Z |
dc.date.available | 2012-07-19T01:41:45Z |
dc.date.issued | 2012 |
dc.identifier.isbn | 978-89-8187-873-3 |
dc.identifier.uri | https://repository.kihasa.re.kr/handle/201002/8684 |
dc.description.tableOfContents | CHAPTER 1 Introduction 3 Section 1. Background 3 Section 2. Purpose 4 Section 3. Contents and Methods 4 CHAPTER 2 Current State of high-cost medicines 9 Section 1. Definition of High-Cost Medicines 9 Section 2. Characteristics of High-Cost Medicines 13 Section 3. Current State of High-Cost Drug Market and Outlook 16 Section 4. Policy Issues Related to high-cost medicines 20 CHAPTER 3 High-Cost Medicines and Relevant Systems in Korea 29 Section 1. High-Cost Medicines in Korea 33 Section 2. Relevant Systems 36 CHAPTER 4 Policy Recommendations in the High-Cost Drug Era 55 Section 1. Insurance Coverage 49 Section 2. Appropriate Utilization 51 Section 3. Enhanced Evidence Development 54 CHAPTER 5 Conclusions 61 References 61 |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | 한국보건사회연구원 |
dc.publisher | Korea Institute for Health and Social Affairs |
dc.rights | Attribution-NonCommercial-NoDerivs 2.0 Korea (CC BY-NC-ND 2.0 KR) |
dc.rights | KOGL BY-NC-ND |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ |
dc.rights.uri | http://www.kogl.or.kr/info/licenseType4.do |
dc.title | Future Directions for Pharmaceutical Policy in the New Era of High Cost Medicines |
dc.type | Book |
dc.type.local | Report |
dc.type.other | Working Paper |
dc.identifier.localId | Working Paper 2012-04 |
dc.subject.kihasa | 식품/의약품 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.